memantine has been researched along with Behavior Disorders in 26 studies
Excerpt | Relevance | Reference |
---|---|---|
"The aim of the study was to determine whether changes in agitation and aggression would follow memantine treatment and, if so, be associated with changes in nursing burden in institutionalized patients with moderate to severe AD." | 9.15 | Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. ( Cappell, J; Eryavec, GM; Herrmann, N; Lanctôt, KL, 2011) |
"Memantine has been proven to reduce brain injury in several types of brain insults." | 5.42 | Memantine alleviates brain injury and neurobehavioral deficits after experimental subarachnoid hemorrhage. ( Cheng, YY; Chio, CC; Huang, CY; Pan, CH; Shan, YS; Tsai, KJ; Wang, HK; Wang, LC, 2015) |
"The aim of the study was to determine whether changes in agitation and aggression would follow memantine treatment and, if so, be associated with changes in nursing burden in institutionalized patients with moderate to severe AD." | 5.15 | Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. ( Cappell, J; Eryavec, GM; Herrmann, N; Lanctôt, KL, 2011) |
" Safety and tolerability were assessed by the number of withdrawals, adverse events (AEs) and monitoring of vital signs." | 2.73 | Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. ( Barker, A; Bayer, A; Inglis, F; Jones, RW; Phul, R, 2007) |
"Memantine is a selective noncompetitive NMDA receptor antagonist that has been shown to decrease alcohol craving in moderate drinkers." | 2.73 | A pilot double-blind treatment trial of memantine for alcohol dependence. ( Brooks, DJ; Evans, SM; Garawi, F; Levin, FR, 2007) |
"This prospective study used a full population pharmacokinetic sampling design." | 2.73 | Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. ( Bleich, S; Kennepohl, EM; Kornhuber, J; Kraus, T; Meineke, I; Reulbach, U; Wiltfang, J, 2007) |
"Kynurenic acid (KYNA) is an antagonist to the α-7nACh and NMDA receptors." | 2.58 | Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement. ( Koola, MM, 2018) |
"Although Parkinson's disease (PD) has been considered to primarily affect motor abilities, increasing emphasis is being placed on cognitive and behavioural impairment in this disorder." | 2.44 | Cognitive and behavioural impairment in Parkinson's disease. ( Freedman, M; Merims, D, 2008) |
"Alzheimer's disease is a chronic, progressive illness that requires long-term management." | 2.43 | Alzheimer's disease care management plan: maximizing patient care. ( Treinkman, A, 2005) |
"Memantine has been proven to reduce brain injury in several types of brain insults." | 1.42 | Memantine alleviates brain injury and neurobehavioral deficits after experimental subarachnoid hemorrhage. ( Cheng, YY; Chio, CC; Huang, CY; Pan, CH; Shan, YS; Tsai, KJ; Wang, HK; Wang, LC, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 13 (50.00) | 29.6817 |
2010's | 11 (42.31) | 24.3611 |
2020's | 2 (7.69) | 2.80 |
Authors | Studies |
---|---|
Whitney, R | 1 |
Jain, P | 1 |
Kern, DM | 1 |
Cepeda, MS | 1 |
Flores, CM | 1 |
Wittenberg, GM | 1 |
Aftab, A | 1 |
Latorre, S | 1 |
Koola, MM | 1 |
Cumbo, E | 1 |
Ligori, LD | 1 |
Wallesch, CW | 1 |
Huang, CY | 1 |
Wang, LC | 1 |
Wang, HK | 1 |
Pan, CH | 1 |
Cheng, YY | 1 |
Shan, YS | 1 |
Chio, CC | 1 |
Tsai, KJ | 1 |
Kuronen, M | 1 |
Koponen, H | 1 |
Nykänen, I | 1 |
Karppi, P | 1 |
Hartikainen, S | 1 |
Cummings, JL | 1 |
Mackell, J | 1 |
Kaufer, D | 1 |
Merims, D | 1 |
Freedman, M | 1 |
Schmidt, R | 1 |
Baumhackl, U | 1 |
Berek, K | 1 |
Brücke, T | 1 |
Kapeller, P | 1 |
Lechner, A | 1 |
Rainer, M | 1 |
Stögerer, EM | 1 |
Supprian, T | 1 |
Höhl, W | 1 |
Herrmann, N | 1 |
Cappell, J | 1 |
Eryavec, GM | 1 |
Lanctôt, KL | 1 |
Sani, G | 1 |
Serra, G | 2 |
Kotzalidis, GD | 1 |
Romano, S | 1 |
Tamorri, SM | 1 |
Manfredi, G | 1 |
Caloro, M | 1 |
Telesforo, CL | 1 |
Caltagirone, SS | 1 |
Panaccione, I | 1 |
Simonetti, A | 1 |
Demontis, F | 1 |
Girardi, P | 1 |
Schwarz, S | 1 |
Froelich, L | 1 |
Burns, A | 1 |
Caban-Holt, A | 1 |
Bottiggi, K | 1 |
Schmitt, FA | 1 |
Treinkman, A | 1 |
Preskorn, SH | 1 |
Borges, S | 1 |
Flockhart, D | 1 |
Jones, RW | 1 |
Bayer, A | 1 |
Inglis, F | 1 |
Barker, A | 1 |
Phul, R | 1 |
Howland, RH | 1 |
Beier, MT | 1 |
Evans, SM | 1 |
Levin, FR | 1 |
Brooks, DJ | 1 |
Garawi, F | 1 |
Kornhuber, J | 1 |
Kennepohl, EM | 1 |
Bleich, S | 1 |
Wiltfang, J | 1 |
Kraus, T | 1 |
Reulbach, U | 1 |
Meineke, I | 1 |
Belmin, J | 1 |
Péquignot, R | 1 |
Konrat, C | 1 |
Pariel-Madjlessi, S | 1 |
Zdanys, K | 1 |
Tampi, RR | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase IV-An Open-Label Prospective Study of Memantine in Institutionalized Patients With Severe Alzheimer's Disease and Significant Behavioural and Psychological Symptoms of Dementia[NCT00401167] | Phase 4 | 32 participants (Anticipated) | Interventional | 2006-11-30 | Completed | ||
Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome[NCT02304302] | Phase 2 | 160 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
This is a measure of adaptive functioning that integrates information from 13 different domains (e.g., gross motor, social interaction, eating, toileting, dressing, personal self-care, etc.). It is in a questionnaire format, which a caregiver can complete while the participant is being tested. Standard scores for all indices will be derived from age norms that extend from birth to age 80, as these were used as dependent variables. We report here on the Broad Independence Score recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the SIB-R Score Scale in this study was -24 (this number is below 0 because -24 was the minimum value for the worst performing participant in the trial) and the maximum value of this scale is 153; higher scores mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 6.88 |
Memantine | 3.23 |
The primary efficacy measure is focused on episodic memory. The CVLT-II short form assesses supraspan word learning ability as an index of episodic verbal long-term memory. We hypothesize that treatment with memantine will produce significant improvements in this test. The main dependent variable selected, based on prior literature was the total number of target items correct summed across learning trials 1-4. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). Scale Range: from 0 to 36; higher scores represent better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 3.3 |
Memantine | 3.49 |
This is a measure of non-verbal memory that requires the participant to learn associations between an abstract visual pattern and its location. Two dependent variables have been selected: Total number of items correct on the first trial of each stage, and total number of stages completed. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the PAL Memory Score Scale is 0 and the maximum value is 21; higher scores mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 1 |
Memantine | 0.67 |
This is a measure of non-verbal memory. Total number correct across the two series of items presented was used as the dependent variable. We used the PRM total scale in this study, which represents the sum of the PRM correct scores (ranging from 0 to 24) and the PRM delayed scores (ranging from 0 to 24). Therefore, the range of the PRM total scale is from 0 to 48; higher values mean better outcomes. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 0.45 |
Memantine | -0.05 |
This is a measure of rote short-term verbal memory. Total number of items correct were used as the dependent variable. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value for this scale is 0 and the maximum value is 38; higher scores mean a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 0.03 |
Memantine | -0.01 |
This measure is a computerized version of the Corsi Blocks task, a long-standing neuropsychological test. The main dependent variables selected for this test was the span length, which is the longest sequence of numbers recalled accurately. The minimum value of the Spatial Span Length Score Scale is 0 and the maximum value is 9; higher scores mean better outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 0.13 |
Memantine | 0.03 |
"The test requires participants to search under a series of colored boxes to locate a blue token hidden underneath one of them. During a series of trials, the participant is told that the token will be in a new location each time and that they should not go back to a location he or she has looked in previously. The main dependent variable was the total number of errors (between errors), which indexes the number of times a participant went back to a box where a token had already been found, lower scores mean better performance. The minimum value of the Spatial Working Memory scale is 0 and the maximum value is 137 (which was computed as the equivalent to -4 standard deviations from the mean of this measure); higher scores mean worse outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2)." (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | -0.09 |
Memantine | -1.4 |
"This is a measure of inhibitory control, often used as a marker for prefrontal-striatal function integrity. Specifically, it measures the participant's ability to inhibit pre-potent behavioral responses that have been established by provision of prior go or no-go cues in a classical conditioning paradigm. The main dependent variables selected was speed of response of execution to Go targets. The minimum value of the speed of response of execution to Go targets is 280 milliseconds (ms) and the maximum value is 1000 ms; higher scores mean worse outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2)." (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | ms (Mean) |
---|---|
Placebo | -2.52 |
Memantine | 0.22 |
This test provides a measure of non-verbal reasoning ability that requires subjects to visually inspect a matrix of 4 or 9 pictures that has a missing piece. Participants have to infer a rule or pattern in the stimuli and select the appropriate response from a range of 4-6 possibilities. Since age norms are not available for individuals older than 17y11m, the ability score will be used as the dependent variable. This is an intermediate score based on Rasch modeling that corrects for different items set being administered to participants. The minimum value of the DAS-II Rasch Score Scale is 0 and the maximum value is 153; higher scores mean better outcomes. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 0.75 |
Memantine | 2.66 |
This is a measure of receptive semantics, whereby the participant is asked to point to a picture (out of 4) that corresponds to a word spoken by the examiner. As this test has a 0.85 correlation with composite measures of Verbal IQ (i.e. from the Wechsler Intelligence Scale series), it can be used in conjunction with the Matrices subtest to estimate overall intellectual functioning. The total number of items correct was used as the dependent variable, following the administration manual's rules for basals and ceilings. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value for this scale is 0 and the maximum value is 192, higher scores mean a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 4.46 |
Memantine | 5.63 |
This is a measure of receptive syntax skills (Bishop, 1983). Participants are asked to point to a picture (out of 4) that corresponds to a phrase or sentence spoken by the examiner. The total number of items correct (rather than blocks passed) will be used as the dependent variable, following the administration manual's ceiling rule. The values for this measure have been recorded as change in score from baseline (T1) to after the treatment (T2). The minimum value of the scores is 0 and the maximum value is 40; with higher scores considered to be a better outcome. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | score on a scale (Mean) |
---|---|
Placebo | 0.49 |
Memantine | 0.89 |
Incidence of adverse events was monitored by clinical history, physical examinations, electrocardiograms (ECGs), clinical laboratory tests, the Screen for Childhood Anxiety Related Emotional Disorders (SCARED). Here, we report the analysis of the effect of memantine treatment on QTc intervals because of its clinical importance for this analysis for potential drug toxicity. QTc intervals ≥ 450 ms are generally considered long, and drug-induced QTc interval prolongations ≥ 60 ms are generally considered clinically relevant. (NCT02304302)
Timeframe: baseline and 16 weeks from start of treatment
Intervention | ms (Mean) |
---|---|
Placebo | -1.30 |
Memantine | -0.11 |
14 reviews available for memantine and Behavior Disorders
Article | Year |
---|---|
Application of Real-World Data and the REWARD Framework to Detect Unknown Benefits of Memantine and Identify Potential Disease Targets for New NMDA Receptor Antagonists.
Topics: Cohort Studies; Databases, Factual; Drug Development; Excitatory Amino Acid Antagonists; Humans; Mem | 2021 |
Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement.
Topics: Animals; Cognitive Dysfunction; Drug Therapy, Combination; Electroconvulsive Therapy; Galantamine; H | 2018 |
[Pharmacological and non-pharmacological treatment of Alzheimer's dementia].
Topics: Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Combined Modality Therapy; Disea | 2013 |
Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Excitatory Amino Acid Antago | 2008 |
Cognitive and behavioural impairment in Parkinson's disease.
Topics: Antiparkinson Agents; Cognition Disorders; Dementia; Disease Progression; Humans; Incidence; Lewy Bo | 2008 |
The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.
Topics: Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; | 2012 |
Pharmacological treatment of dementia.
Topics: Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; | 2012 |
Measuring treatment response in Alzheimer's disease clinical trials.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antiparkinson Agents; Clinical Trials as Topic; | 2005 |
Alzheimer's disease care management plan: maximizing patient care.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Management; Disease Progression; Excitatory Am | 2005 |
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Alzheimer Disease; Brain; Dopamine Agents; Humans; Mema | 2006 |
Glutamate-modulating drugs & the treatment of mental disorders.
Topics: Acamprosate; Amantadine; Cycloserine; Glutamic Acid; Humans; Ketamine; Lamotrigine; Memantine; Menta | 2007 |
Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Men | 2007 |
[Management of Alzheimer disease].
Topics: Aged; Alzheimer Disease; Animals; Antipsychotic Agents; Caregivers; Case Management; Cholinesterase | 2007 |
A systematic review of off-label uses of memantine for psychiatric disorders.
Topics: Anxiety; Bipolar Disorder; Bulimia Nervosa; Child; Child Development Disorders, Pervasive; Depressio | 2008 |
6 trials available for memantine and Behavior Disorders
Article | Year |
---|---|
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia | 2014 |
[Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Austria; Ca | 2010 |
Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
Topics: Aggression; Alzheimer Disease; Caregivers; Dopamine Agents; Female; Humans; Long-Term Care; Male; Me | 2011 |
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anxiety; Dopamine Agents; Double-Blind Method; Drug Admi | 2007 |
A pilot double-blind treatment trial of memantine for alcohol dependence.
Topics: Adult; Affect; Alcoholism; Data Interpretation, Statistical; Double-Blind Method; Excitatory Amino A | 2007 |
Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antiparkinson Agents; Biological Availability; Drug A | 2007 |
6 other studies available for memantine and Behavior Disorders
Article | Year |
---|---|
Memantine: a novel treatment for children with developmental and epileptic encephalopathies.
Topics: Child; Cross-Over Studies; Epilepsy; Epilepsy, Generalized; Humans; Memantine; Mental Disorders | 2023 |
Geriatric-Onset Olfactory Reference Syndrome Successfully Treated with Duloxetine and Memantine.
Topics: Age of Onset; Aged; Comorbidity; Duloxetine Hydrochloride; Female; Humans; Memantine; Mental Disorde | 2017 |
Memantine alleviates brain injury and neurobehavioral deficits after experimental subarachnoid hemorrhage.
Topics: Animals; Brain Injuries; Excitatory Amino Acid Antagonists; Male; Memantine; Mental Disorders; Motor | 2015 |
Use of anti-dementia drugs in home care and residential care and associations with neuropsychiatric symptoms: a cross-sectional study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cross-Sectional Stud | 2015 |
[Treatment of dementia].
Topics: Aged; Alzheimer Disease; Antidepressive Agents; Central Nervous System Stimulants; Cholinesterase In | 2010 |
[Also consider non-cognitive disorders].
Topics: Aged; Alzheimer Disease; Brain; Cognition Disorders; Depressive Disorder; Excitatory Amino Acid Anta | 2005 |